Protagonist Therapeutics Inc - Asset Resilience Ratio
Protagonist Therapeutics Inc (PTGX) has an Asset Resilience Ratio of 65.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Protagonist Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Protagonist Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PTGX total assets.
Liquid Assets Composition Over Time
This chart breaks down Protagonist Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Protagonist Therapeutics Inc (PTGX) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $462.40 Million | 65.9% |
| Total Liquid Assets | $462.40 Million | 65.90% |
Asset Resilience Insights
- Very High Liquidity: Protagonist Therapeutics Inc maintains exceptional liquid asset reserves at 65.90% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Protagonist Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Protagonist Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Protagonist Therapeutics Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Protagonist Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 43.19% | $321.66 Million | $744.73 Million | -0.08pp |
| 2023-12-31 | 43.27% | $154.89 Million | $357.95 Million | -1.75pp |
| 2022-12-31 | 45.02% | $111.61 Million | $247.93 Million | -13.43pp |
| 2021-12-31 | 58.45% | $203.24 Million | $347.69 Million | +0.37pp |
| 2020-12-31 | 58.08% | $188.45 Million | $324.47 Million | -6.48pp |
| 2019-12-31 | 64.56% | $100.01 Million | $154.92 Million | +31.13pp |
| 2018-12-31 | 33.43% | $46.62 Million | $139.47 Million | +10.23pp |
| 2017-12-31 | 23.19% | $37.97 Million | $163.73 Million | -36.94pp |
| 2016-12-31 | 60.13% | $56.52 Million | $93.99 Million | +7.13pp |
| 2015-12-31 | 53.00% | $7.87 Million | $14.85 Million | +52.90pp |
| 2014-12-31 | 0.10% | $10.00K | $10.33 Million | -- |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical tri… Read more